We are live on ! Find out more
GILD icon

Gilead Sciences

1,522 hedge funds and large institutions have $72.7B invested in Gilead Sciences in 2018 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 544 increasing their positions, 725 reducing their positions, and 107 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 78.96%79% (+0.04%)

3% less funds holding

Funds holding: 1,5631,522 (-41)

6% less capital invested

Capital invested by funds: $77.5B → $72.7B (-$4.82B)

22% less funds holding in top 10

Funds holding in top 10: 6047 (-13)

25% less repeat investments, than reductions

Existing positions increased: 544 | Existing positions reduced: 725

29% less first-time investments, than exits

New positions opened: 76 | Existing positions closed: 107

31% less call options, than puts

Call options by funds: $1.25B | Put options by funds: $1.82B

Holders
1,522
Holders Change
-41
Holders Change %
-2.62%
% of All Funds
34.84%
Holding in Top 10
47
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-21.67%
% of All Funds
1.08%
New
76
Increased
544
Reduced
725
Closed
107
Calls
$1.25B
Puts
$1.82B
Net Calls
-$567M
Net Calls Change
-$452M
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
526
Stonebridge Capital Management
California
$4.55M +$820K +11,615 +23%
SPC
527
Salient Private Client
Texas
$4.5M -$280K -3,969 -6%
CM
528
Columbus Macro
Pennsylvania
$4.49M +$4.48M +63,414 New
VRS
529
Virginia Retirement Systems
Virginia
$4.44M -$1.48M -20,900 -25%
AAP
530
Aristotle Atlantic Partners
Florida
$4.43M -$2.4M -34,000 -35%
FNBT
531
FineMark National Bank & Trust
Florida
$4.43M +$180K +2,555 +4%
Walleye Trading
532
Walleye Trading
New York
$4.4M -$7.58M -107,401 -63%
MAM
533
Martingale Asset Management
Massachusetts
$4.39M +$240K +3,393 +6%
BIP
534
Brandes Investment Partners
California
$4.38M +$58.2K +824 +1%
LD
535
Lipe & Dalton
New York
$4.36M +$774K +10,966 +22%
OIA
536
Optimum Investment Advisors
Illinois
$4.32M -$51.3K -727 -1%
VBFG
537
Vishria Bird Financial Group
Tennessee
$4.31M +$4.29M +60,804 New
Brown Advisory
538
Brown Advisory
Maryland
$4.28M +$14.3K +203 +0.3%
CCM
539
Compton Capital Management
Rhode Island
$4.23M -$38.6K -547 -0.9%
II
540
IFM Investors
Australia
$4.19M +$1.31M +18,536 +46%
EIM
541
Essex Investment Management
Massachusetts
$4.18M -$13.6K -193 -0.3%
Twin Tree Management
542
Twin Tree Management
Texas
$4.17M -$1.53M -21,710 -27%
AMM
543
American Money Management
California
$4.13M -$332K -4,698 -7%
AIM
544
ARGA Investment Management
Connecticut
$4.12M +$371K +5,250 +10%
ECM
545
Element Capital Management
New York
$4.12M +$2.75M +38,993 +204%
SI
546
Stephens Inc
Arkansas
$4.11M -$215K -3,043 -5%
GAB
547
German American Bancorp
Indiana
$4.11M +$4.09M +57,961 New
FB
548
Fulton Bank
Pennsylvania
$4.05M +$2.97K +42 +0.1%
WS
549
Wedbush Securities
California
$4M -$414K -5,867 -9%
PIA
550
Piedmont Investment Advisors
North Carolina
$3.96M -$9.93M -140,632 -72%

GILD Hedge Fund Activity: Q2 2018 in Review

1,522 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2018, worth a combined $72.7B — down 6.2% from $77.5B a quarter earlier.

Sellers outnumbered buyers: 107 funds closed out of GILD and 76 opened new positions — a net loss of 31 holders — while 725 trimmed existing stakes and 544 added.

The largest buyer was Capital Research Global Investors, adding an estimated $995M. The largest seller was Fidelity Investments, cutting an estimated $361M.

  • 1,522 institutional investors held Gilead Sciences (GILD) as of Q2 2018, down from 1,563 in Q1 2018.
  • Funds reported $72.7B of Gilead Sciences stock for Q2 2018, down 6.2% quarter-over-quarter.
  • 76 funds opened new Gilead Sciences positions in Q2 2018 and 107 closed out, a net change of -31 holders.
  • The largest Gilead Sciences buyer in Q2 2018 was Capital Research Global Investors, an estimated $995M added.
  • The largest Gilead Sciences seller in Q2 2018 was Fidelity Investments, an estimated $361M sold.

Based on aggregated 13F filings for Q2 2018.